Regina Berger

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

Isabelle Ray‐Coquard, Patricia Pautier, Sandro Pignata et al. · New England Journal of Medicine · 2019 · 2K citations · Full text

Medicine, Oncology, Pharmacotherapy +14

MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum

Bradley J. Monk, Rachel N. Grisham, Susana Banerjee et al. · Journal of Clinical Oncology · 2020 · 153 citations · Full text

Medicine, Oncology, Pharmacology +17

Lidocaine time- and dose-dependently demethylates deoxyribonucleic acid in breast cancer cell lines in vitro

Philipp Lirk, Regina Berger, Markus W. Hollmann et al. · British Journal of Anaesthesia · 2012 · 131 citations

Medicine, Oncology, Pharmacology +13

Toll‐like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors

Regina Berger, Heidi Fiegl, Petra Obexer et al. · Cancer Science · 2010 · 87 citations · Full text

Life Sciences, Immunology, Oncology +12

ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer

Christian Marth, Ignace Vergote, Giovanni Scambia et al. · European Journal of Cancer · 2016 · 80 citations

Medicine, Oncology, Pharmacology +13